Richard Lindstrom, MD, to Lead Eye Care Biopharmaceutical Company Surface Ophthalmics

Surface Ophthalmics announced the appointment of Richard Lindstrom, MD, as Founder and Chairman. Dr. Lindstrom is founder and attending surgeon emeritus at Minnesota Eye Consultants, PA. Dr. Lindstrom will lead in partnership with Surface’s Board of Directors, including Adrienne Graves, PhD, (Lead Director); Perry J. Sternberg, Shelley Thunen, and J. Andy Corley.

Surface seeks to address the full range of dry eye syndrome, from episodic to chronic by providing eye care professionals targeted therapies to treat the signs, symptoms, and underlying causes of DES, which can be naturally occurring or following ocular surgery.

“I am honored and thrilled to lead Surface Ophthalmics into its next phase of expansion as we work to advance the company’s innovative and proprietary medicinal candidates for patients suffering from DES,” Dr. Lindstrom said in a company news release. “Our solutions hold significant potential to meet existing gaps in care, and I’m eager to collaborate with our talented team to introduce these products to the market.”

Surface Ophthalmics is advancing two products:

• Kera Sol Tears, an over-the-counter artificial tear solution designed for cell-compatible, short-term, fast-acting, temporary relief of burning and irritation caused by dryness of the eye.
• Investigational drug Mycosol (Surf-101), a first-in-class prescription eye drop that delivers Mycophenolate in Surface’s proprietary formulation. This combination is designed to provide sustained immunosuppressive action and mucin upregulation at the ocular surface.